Cubist Systematic Strategies LLC Raises Stock Position in Orthofix Medical Inc. $OFIX

Cubist Systematic Strategies LLC raised its holdings in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 161.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 78,220 shares of the medical device company's stock after buying an additional 48,353 shares during the period. Cubist Systematic Strategies LLC owned about 0.20% of Orthofix Medical worth $1,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Orthofix Medical by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company's stock valued at $338,000 after buying an additional 836 shares in the last quarter. Gamco Investors INC. ET AL lifted its stake in shares of Orthofix Medical by 1.0% in the first quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company's stock valued at $2,562,000 after buying an additional 1,500 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Orthofix Medical by 5.9% in the fourth quarter. BNP Paribas Financial Markets now owns 36,798 shares of the medical device company's stock valued at $642,000 after buying an additional 2,040 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Orthofix Medical by 7.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 36,425 shares of the medical device company's stock valued at $636,000 after buying an additional 2,507 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Orthofix Medical in the fourth quarter valued at $45,000. 89.76% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on OFIX. Barrington Research raised shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 price target on the stock in a research report on Monday, June 23rd. Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $21.50.

Insider Buying and Selling at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total value of $39,181.28. Following the completion of the transaction, the insider owned 46,322 shares in the company, valued at $486,844.22. This trade represents a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by insiders.

Orthofix Medical Stock Performance

Shares of OFIX traded down $0.09 during trading hours on Friday, hitting $14.91. The company's stock had a trading volume of 517,542 shares, compared to its average volume of 430,615. The company has a market cap of $588.86 million, a price-to-earnings ratio of -4.70 and a beta of 0.86. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50. The business has a 50 day simple moving average of $12.90 and a two-hundred day simple moving average of $13.24. Orthofix Medical Inc. has a 52-week low of $10.24 and a 52-week high of $20.73.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.40). The business had revenue of $203.12 million during the quarter, compared to analysts' expectations of $196.89 million. Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.